Table 2 Results at baseline and 1 month in both the Losartan and Placebo groups
Variable | Losartan (A) baseline | Losartan (B) 1 month | Placebo (A) baseline | Placebo (B) 1 month | P |
|---|---|---|---|---|---|
sSBP (mmHg) | 142 (132–160) | 129 (117–149)a | 137 (130–153.5) | 138 (127–141.5) | A ns B ns |
sDBP (mmHg) | 74 (72–80) | 70 (64–84) | 78 (70–86) | 79 (70–85.5) | A ns B ns |
sHR (bpm) | 64 (60–74) | 62 (56–80) | 68 (61–74) | 72 (66–78) | A ns B ns |
BNP | 285 (65–1194) | 325 (206–1798.5) | 163 (63–303.3) | 214 (144–277.5) | A ns B ns |
LVM (gm) | 199.1 (148.5–225.2) | 218.4 (146.5–262.2)a | 182.7 (143.5–205.0) | 173.8 (151.1–204.9) | A ns B ns |
LVMI (gm/m2) | 99.6 (72.8–114.3) | 83.5 (69.8–112) | 91.3 (77.6–106.8) | 92.7 (78.4–107.5) | A ns B ns |
RWT | 0.40 (0.32–0.45) | 0.36 (0.32–0.41) | 0.40 (0.34–0.47) | 0.37 (0.35–0.42) | A ns B ns |
CO (L/min) | 5.3 (4.5–5.6) | 5.9 (4.5–7.3) | 4.4 (3.7–5.9) | 5.3 (4.6–6.9) | A ns B ns |
E/E’ | 15.0 (10.0–21.0) | 12 (8.8–17.3) | 11.4 (9.8–14.0) | 10.4 (8.8–13.2)a | A ns B ns |
LAV (mLs) | 66.5 (54.8–75.6) | 74.3 (59.8–80.5) | 65.0 (50.1–82.2) | 65.1 (59.4–81.3) | A ns B ns |
EF (%) | 55 (47–57.8) | 52.5 (49.3–56.8) | 52.5 (47.8–58.8) | 52 (51–60) | A ns B ns |